Trials / Completed
CompletedNCT06224192
A Study With Self-administered Rocatinlimab in Adolescent and Adult Participants With Moderate-to-severe Atopic Dermatitis
A Phase 3, Multicenter, Randomized, Open-label, Performance Study With Self-administered Subcutaneous Rocatinlimab (AMG 451) in Adolescent and Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Outpost)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 151 (actual)
- Sponsor
- Amgen · Industry
- Sex
- All
- Age
- 12 Years – 100 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to assess successful self-administration of rocatinlimab subcutaneously using devices for injection.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| COMBINATION_PRODUCT | Rocatinlimab Prefilled Syringe | Prefilled Syringe (PFS) for subcutaneous (SC) injection self-administration of rocatinlimab. |
| COMBINATION_PRODUCT | Rocatinlimab AI | AI for SC injection self-administration of rocatinlimab. |
Timeline
- Start date
- 2024-04-02
- Primary completion
- 2025-04-11
- Completion
- 2026-03-16
- First posted
- 2024-01-25
- Last updated
- 2026-03-25
Locations
47 sites across 4 countries: United States, Canada, Japan, South Korea
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06224192. Inclusion in this directory is not an endorsement.